Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of the Atypical Antipsychotic Quetiapine in the Treatment of Postpartum Depressive Disorder With Psychotic Symptoms

NCT00681668 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00681668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00681668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of the Atypical Antipsychotic Quetiapine in the Treatment of Postpartum Depressive Disorder With Psychotic Symptoms
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2007
Completion date
October 31, 2008
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

postpartum depressive disorder